Drug Search Results
More Filters [+]

Volasertib

Alternative Names: volasertib, bi 6727, bi-6727
Latest Update: 2024-08-29
Latest Update Note: News Article

Product Description

Volasertib is a dihydropteridinone Polo-like kinase 1 (Plk1) inhibitor with potential antineoplastic activity. Volasertib selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Volasertib)

Mechanisms of Action: PLK1 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: Orphan Drug - Myosarcoma|Rhabdomyosarcoma|Sarcoma *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Volasertib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Acute Myeloid Leukemia|Leukemia|Stem Cell Transplant

Phase 2: Bladder Cancer|Transitional Cell Carcinoma|Kidney Diseases|Myelodysplastic Syndrome|Ovarian Cancer|Acute Myeloid Leukemia|Non-Small-Cell Lung Cancer|Leukemia|Preleukemia

Phase 1: Myelodysplastic Syndrome|T-Cell Peripheral Lymphoma|Oncology Solid Tumor Unspecified|Preleukemia|T-Cell Lymphoma|Leukemia|Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Myelomonocytic Leukemia|Acute Monocytic Leukemia|Juvenile Myelomonocytic Leukemia,|Acute Erythroblastic Leukemia|Acute Megakaryoblastic Leukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

POLO-AML-2

P3

Completed

Leukemia

2021-05-28

2008-003617-27

P2

Completed

Leukemia

2021-04-23

JapicCTI-132264

P3

Completed

Acute Myeloid Leukemia

2019-10-31

NU 16H06

P1

Withdrawn

Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma

2018-07-01

Recent News Events